ping liqin

Dr. ping liqin

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 August 2022 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
PLping liqin
ping liqin
YGYan Gao
Yan Gao
YHYanxia He
Yanxia He
XWXiaoxiao Wang
Xiaoxiao Wang
BBBing Bai
Bing Bai
HHHui-Qiang Huang
Hui-Qiang Huang
Background. T lymphoblastic lymphoma/leukemia (T‐LBL/ALL) is an aggressive malignant tumor with 5‐year overall survival (OS) rate reached 80% after high‐dose chemotherapy. Due to the relatively low incidence of T‐LBL/ALL, only a few risk factors have been identified. The occurrence and prognosis of malignant tumors are closely related to oxidative stress, but the prognostic relationship between T‐LBL/ALL and systematic oxidative stress indexes has not been reported yet. Methods. A total of 258 T‐LBL/ALL patients were retrospectively analyzed. The relationship between systematic oxidative stress indexes, such as creatinine (CRE), gamma‐glutamyl transpeptidase (γ‐GGT), albumin (ALB), alkaline phosphatase (ALP), fibrinogen (FBG), C‐reactive protein (CRP) and total bilirubin (TBIL), and survival of T‐LBL/ALL patients, was analyzed. The weight of indexes was used to calculate the patients' oxidative stress risk score. The independent prognostic value of oxidative stress risk grouping (OSRG) was analyzed. Results. Higher CRE, CRP, and lower ALB were associated with poorer OS in T‐LBL/ALL patients. The OSRG established by CRE, ALB, and CRP was an independent prognostic factor for OS of T‐LBL/ALL patients. Patients in the high‐risk group were more likely to be patients older than 14 years old and patients with superior vena cava obstruction syndrome (SVCS), pleural effusion, pericardial effusion, and mediastinal mass. Conclusion. For OS in T‐LBL/ALL patients, OSRG was observed as an independent prognostic factor, which provided a new idea for accurate prognostic prediction.

Verified
Journal Article
Open access
PDF file
PLping liqin
ping liqin
YHYanxia He
Yanxia He
YGYan Gao
Yan Gao
XWXiaoxiao Wang
Xiaoxiao Wang
CHCheng Huang
Cheng Huang
HHHui-Qiang Huang
Hui-Qiang Huang
Background: Diffuse large B-cell lymphoma (DLBCL) is the most prevalent type of lymphoma that is potentially curable by chemotherapy. Immunogenic cell death (ICD) is regarded as an essential process for the clearance of residual tumor cells. However, the impact of ICD on DLBCL remains unknown. Here, we tried to explore the prognostic role of ICD in DLBCL. Methods: A gene expression microarray of DLBCL was downloaded from the Gene Expression Omnibus (GEO). The genes involved in ICD were obtained via literature reviews. Then, based on univariate, multivariate, and LASSO Cox regression analysis, the ICD-related gene signature was identified. The effect of the ICD-related gene signature on DLBCL was explored. The chi-square test was used to compare complete response rate (CRR) and recurrence rate between high- and low-risk groups. Results: The signature based on 12 ICD-related genes could independently predict the overall survival of DLBCL. Furthermore, high risk was linked to lower CRR and higher recurrence rate. Then, a nomogram based on the ICD-related gene signature was established. The area under the curve of the prediction model reached 0.820 in the training set and 0.780 in the validation set. Conclusions: This study suggested that the ICD-related gene signature could be a novel prognostic indicator for DLCBL.

Verified
Journal Article
Open access
PDF file
KZKaiming Zhang
Kaiming Zhang
PLping liqin
ping liqin
XOXueqi Ou
Xueqi Ou
MBMeiheban Bazhabayi
Meiheban Bazhabayi
XXXiangsheng Xiao
Xiangsheng Xiao
Background: Systemic inflammatory response is related to the occurrence, progression, and prognosis of cancers. In this research, a novel systemic inflammation response score (SIRS) was calculated, and its prognostic value for postoperative stage I-III breast cancer (BC) patients was analyzed. Methods: 1583 BC patients were included in this research. Patients were randomly divided into a training cohort (n = 1187) and validation cohort (n = 396). SIRS was established in the training cohort based on independent prognostic hematological indicator, its relationship between prognosis and clinical features was analyzed. Then, a nomogram consisted of SIRS and clinical features was established, its performance was examined by calibration plots and receiver operating characteristic curve analysis. Results: The SIRS was an independent prognostic indicator for BC patients, and a high-SIRS was related to multifocality, advanced N stage, and worse prognosis. Incorporating SIRS into a nomogram could accurately predict the prognosis of BC patients, the results of receiver operating characteristic (ROC) curve analysis showed that the area under the curve (AUC) of nomogram was up to 0.806 in training cohort and 0.905 in the validation cohort. Conclusion: SIRS was associated with the prognosis of patients with breast cancer. Nomogram based on SIRS can accurately predict the prognosis of breast cancer patients.

11 February 2025 in Annals of Hematology
Verified
Journal Article
Open access
PDF file
CHCheng Huang
Cheng Huang
YLYi Li
Yi Li
HHHaixia He
Haixia He
YGYan Gao
Yan Gao
XZXu Zhang
Xu Zhang
HHHui-Qiang Huang
Hui-Qiang Huang
The aim of this study was to investigate the prognostic value of baseline PET/CT parameters alone and combined with clinical features in Extranodal Natural killer/T-cell lymphoma (ENKTL) patients treated with P-GEMOX regimen (pegaspargase, gemcitabine and oxaliplatin). A total of 97 patients were retrospectively evaluated. The relationships between baseline PETCT metabolic parameters and survival were tested using Cox regression analysis and receiver operating characteristic(ROC) curve analysis was employed to evaluate the optimal cut-off value of these parameters. Kaplan–Meier curves with log-rank tests were used for survival analysis. At a median follow-up of 49 months, the 3-year PFS and OS were 62.9% and 70.1%. SUVmean, SUVmax, and SUVpeak were related to both PFS and OS in univariate analysis(P < 0.05 for all). Further multivariate analysis including PET/CT parameters and clinical parameters revealed that SUVmean was an independent prognostic factor and seemed to be slightly superior to SUVmax and SUVpeak. The low SUVmean was significantly associated with a better prognosis (3-year OS 85.1% vs.65.0%, P = 0.014; 3-year PFS 76.8% vs.62.1%, P = 0.032). SUVmean was able to further separate patients with a low-risk PINK/PINKE of < 2(n = 85, 79, separately) into two subgroups with significantly different outcomes. Moreover, the metabolic-parameter-contained m-PINK/PINKE model was constructed and showed superior predictive performance in the whole cohort. Conclusions. SUVmean was an independent prognostic factor in patients with ENKTL treated with P-GEMOX chemotherapy. Adding SUVmean to the PINK or PINKE model could improve the predictive value and further distinguish patients with poor outcomes.